MARKET

TVTX

TVTX

Travere Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.44
-1.09
-4.63%
Closed 17:47 09/16 EDT
OPEN
23.43
PREV CLOSE
23.53
HIGH
23.43
LOW
21.91
VOLUME
1.16M
TURNOVER
--
52 WEEK HIGH
33.09
52 WEEK LOW
12.75
MARKET CAP
1.36B
P/E (TTM)
-5.0722
1D
5D
1M
3M
1Y
5Y
8 Health Care Stocks With Unusual Options Alerts In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to ...
Benzinga · 17h ago
Wedbush Adjusts Travere Therapeutics PT to $14 From $15, Maintains Neutral Rating
MT Newswires · 23h ago
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand
Regulatory News:
Business Wire · 1d ago
Travere Therapeutics, Vifor Pharma Enter Licensing Deal for Commercialization of Sparsentan
MT Newswires · 1d ago
LAUR, LPTX, AERI and TWKS among after hours movers
Gainers: TMC +8.2%. LAUR +7.6%. LPTX +6.7%. TTD +5.9%. GREE +4.4%. Losers: AERI -15.3%. TWKS -4.8%. TVTX -4.3%. PEGA -3.9%. MTCR -3.5%
Seekingalpha · 1d ago
Travere Therapeutics And Vifor Pharma Announce Licensing Agreement For The Commercialization Of Sparsentan In Europe, Australia And New Zealand
Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand Travere receives a $55 million upfront payment and is eligible for additional regulatory and
Benzinga · 1d ago
BRIEF-Travere Therapeutics Appoints Ruth Williams-Brinkley To Its Board Of Directors
reuters.com · 2d ago
Travere Therapeutics Appoints Kaiser Foundation Executive Ruth Williams-Brinkley to Board
MT Newswires · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TVTX. Analyze the recent business situations of Travere Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TVTX stock price target is 32.71 with a high estimate of 42.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 195
Institutional Holdings: 64.56M
% Owned: 106.32%
Shares Outstanding: 60.72M
TypeInstitutionsShares
Increased
49
10.72M
New
20
1.63M
Decreased
43
8.33M
Sold Out
36
5.43M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.83%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Chairman/Director
Gary Lyons
President/Chief Executive Officer/Director
Eric Dube
Chief Financial Officer
Laura Clague
Senior Vice President/General Counsel/Secretary
Elizabeth Reed
Senior Vice President
William Rote
Other
Peter Heerma
Other
Noah Rosenberg
Director
Stephen Aselage
Independent Director
Roy Baynes
Independent Director
Suzanne Bruhn
Independent Director
Timothy Coughlin
Independent Director
Jeffrey Meckler
Independent Director
John Orwin
Independent Director
Sandra Poole
Independent Director
Ron Squarer
Independent Director
Ruth Williams-brinkley
No Data
About TVTX
Travere Therapeutics Inc., formerly Retrophin Inc., is a biopharmaceutical company. The Company specializing in identifying, developing and delivering therapies to people living with rare disease. It's pipeline includes sparsentan (RE-021), a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). Sparsentan is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A and a potent angiotensin receptor blocker (ARB). It's pipeline also includes also include OT-58, an investigational human enzyme replacement therapy. OT-58 is being developed for the treatment of classical homocystinuria (HCU). The Company's commercial products include Chenodal, Cholbam, Thiola and Thiola EC.

Webull offers kinds of Travere Therapeutics Inc stock information, including NASDAQ:TVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TVTX stock methods without spending real money on the virtual paper trading platform.